NCT00502164View on ClinicalTrials.gov

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2004

Conditions
Advanced Prostate Adenocarcinoma
Interventions
DRUG

AZD2171

Trial Locations (3)

Unknown

Research Site, San Francisco

Research Site, Chicago

Research Site, Nashville

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY